Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location

Melanoma Clinical Trials

A listing of Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (296) clinical trials

Safety Tolerability and Pharmacokinetic Study of MRG-106 in Patients With Cutaneous T Cell Lymphoma (CTCL) MF Subtype

Study Design: - Part A: Cohorts of 3-6 patients will receive up to five intratumoral injections of MRG-106 over a period of up to 15 days with follow-up for an additional 20 days, beginning with the maximum deliverable intratumoral dose. Doses may be decreased in subsequent cohorts to determine the ...

Phase

Multi-Centre Retrospective Open Label Study to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy

The aim of this project is to develop a technology application (termed ML-PrediCare), which is meant to be a predictive stand-alone software device, to support clinicians' decision-making, by predicting the individual patient's response to immunotherapy treatments, e.g., in terms of time-to-progression (TTP). In Stage I of the study, data will ...

Phase N/A

Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma

The purpose of this study is to evaluate the efficacy and safety of two different schedules of administration of vemurafenib in combination with cobimetinib (continuous and intermittent) in previously untreated BRAFV600- mutation positive patients with unresectable locally advanced or metastatic melanoma.

Phase

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

In this phase I, open-label, multi-arm, multicentre, multi-dose dose escalation study in patients with transdermally accessible tumours; the safety, PK and efficacy of different dosing regimens of LTX-315 will be assessed. Patients will be allocated into 4 separate (parallel) arms depending on the tumour type and the number of lesions ...

Phase

A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma

The primary objective of this study is: • To evaluate compliance with the administration of standard HDI versus PEG IFN for patients with melanoma in need of adjuvant therapy The secondary objectives of this study are: - To compare the convenience and satisfaction with chemotherapy for patients on standard HDI ...

Phase N/A

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Weekly ADI-PEG 20 will be cohort dose escalated (18, 27 and 36 mg/m2), with pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 both given every 3 weeks. Subjects may receive a maximum of 6, 3-week cycles of ADIPemCis for a total of 18 weeks of treatment. Subjects with NSCLC may receive ...

Phase

Immunotherapy Study for Patients With Stage IV Melanoma

According to statistics of the American Cancer Society, an estimated 73,800 individuals will be diagnosed with melanoma and 9,900 will die of the disease in 2015 in the Unites States despite current therapy. This protocol attempts to exploit an approach to melanoma immunotherapy using a naturally occurring barrier to xenotransplantation ...

Phase

Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging

A topical agent is applied to suspicious skin lesions and imaged. The images are analyzed to provide a score that correlates with the probability for the presence of melanoma in the lesion.

Phase N/A

CNS and Extracranial Tumor Tissues CSF and Blood From Patients With Melanoma Brain Metastases

Among the different sites to which melanoma can spread, the Central Nervous System (CNS) has the highest chance of developing metastases. Prognosis for metastatic melanoma involving the CNS is worse than that of CNS metastases from other cancers. Therefore, it is felt that early identification of this condition, even before ...

Phase N/A

Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma

PRIMARY OBJECTIVES: 1) To assess the efficacy of adjuvant sunitinib malate or adjuvant valproic acid used for 6 months to improve overall survival (OS) at 2 years in patients with high-risk uveal melanoma. SECONDARY OBJECTIVES: 1. To assess the efficacy of adjuvant sunitinib malate and adjuvant valproic acid used for ...

Phase